Protopic Phase IV Pediatric PK Studies Are Required By June 2002
Executive Summary
Fujisawa will conduct postmarketing Protopic pediatric pharmacokinetic studies on children ages two to five following NDA approval of the topical dermatitis drug Dec. 8 for adults and children two years and older.
You may also be interested in...
Novartis Atopic Dermatitis Drug Elidel Launch Projected For 2002
Novartis is planning a U.S. launch for its atopic dermatitis cream Elidel in 2002 following an NDA filing on Dec. 15.
Novartis Atopic Dermatitis Drug Elidel Launch Projected For 2002
Novartis is planning a U.S. launch for its atopic dermatitis cream Elidel in 2002 following an NDA filing on Dec. 15.
Fujisawa Protopic TV Test Market Part Of Dermatitis Drug DTC Campaign
Fujisawa will test market a Protopic (tacrolimus) direct-to-consumer television campaign in January in select cities as part of a multi-prong advertising effort to back the February launch of the dermatitis therapy.